{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:00:07Z","timestamp":1792724407005,"version":"4.5.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.addr.2011.11.006","type":"journal-article","created":{"date-parts":[[2011,11,22]],"date-time":"2011-11-22T07:34:41Z","timestamp":1321947281000},"page":"887-895","source":"Crossref","is-referenced-by-count":123,"title":["Chemical properties of antiepileptic drugs (AEDs)"],"prefix":"10.1016","volume":"64","author":[{"given":"Meir","family":"Bialer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2011.11.006_bb0005","series-title":"Valproate","first-page":"47","article-title":"Chemistry and biotransformation","author":"Abbott","year":"1999"},{"key":"10.1016\/j.addr.2011.11.006_bb0010","series-title":"Treatment of Epilepsy","first-page":"485","article-title":"Eslicarbazepine acetate","author":"Almeida","year":"2009"},{"key":"10.1016\/j.addr.2011.11.006_bb0015","series-title":"Antiepileptic Drugs","first-page":"371","article-title":"Phenobarbital \u2014 chemistry and pharmacokinetics and biotransformation","author":"Anderson","year":"1995"},{"key":"10.1016\/j.addr.2011.11.006_bb0020","series-title":"New Anticonvulsant Drugs","first-page":"147","article-title":"Gabapentin","author":"Bartoszyk","year":"1986"},{"key":"10.1016\/j.addr.2011.11.006_bb0025","series-title":"Antiepileptic Drugs","first-page":"855","article-title":"Vigabatrin","author":"Ben-Menachem","year":"2002"},{"key":"10.1016\/j.addr.2011.11.006_bb0030","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1399-5618.2010.00828.x","article-title":"Valnoctamide as valproate substitute with low teratogenc potential in mania: double blind controlled clinical trial","volume":"12","author":"Bersudsky","year":"2010","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.addr.2011.11.006_bb0035","doi-asserted-by":"crossref","first-page":"114","DOI":"10.2165\/00003088-199120020-00003","article-title":"Clinical pharmacology of valpromide","volume":"20","author":"Bialer","year":"1991","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.addr.2011.11.006_bb0040","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/BF01870931","article-title":"Can we develop improved derivatives of valproic acid?","volume":"16","author":"Bialer","year":"1994","journal-title":"Pharm. World Sci."},{"key":"10.1016\/j.addr.2011.11.006_bb0045","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0168-3659(99)00037-1","article-title":"Pharmacokinetic considerations in the design of better and safer new antiepileptic drugs","volume":"62","author":"Bialer","year":"1999","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2011.11.006_bb1000","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0920-1211(98)00108-9","article-title":"Progress report on new antiepileptic drugs: a summary of the forth Eilat Conference (EILAT IV)","volume":"34","author":"Bialer","year":"1999","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.addr.2011.11.006_bb0050","series-title":"Antiepileptic Drugs","first-page":"459","article-title":"Oxcarbazepine: chemistry, biotransformation and pharmacokinetics","author":"Bialer","year":"2002"},{"key":"10.1016\/j.addr.2011.11.006_bb0055","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.yebeh.2004.08.021","article-title":"Correlation analysis between nariconvulsnat-ED50 values of antiepileptic drugs in mice and rats and their therapeutic doses and plasma levels","volume":"5","author":"Bialer","year":"2004","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.addr.2011.11.006_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2004.07.010","article-title":"Progress report on new antiepileptic drugs: a summary of the ninth Eilat Conference (EILAT VII)","volume":"61","author":"Bialer","year":"2004","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.addr.2011.11.006_bb0065","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1517\/13543784.15.6.637","article-title":"New antiepileptic drugs that are second generation to existing antiepileptic drugs","volume":"15","author":"Bialer","year":"2006","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.addr.2011.11.006_bb1005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2006.10.008","article-title":"Progress report on new antiepileptic drugs: a summary of the eighth Eilat Conference (EILAT VIII)","volume":"73","author":"Bialer","year":"2007","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.addr.2011.11.006_bb0070","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.nurt.2006.11.007","article-title":"Valproic acid \u2014 second generation","volume":"4","author":"Bialer","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.addr.2011.11.006_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2008.09.005","article-title":"Progress report on new antiepileptic drugs: a summary of the ninth Eilat Conference (EILAT IX)","volume":"83","author":"Bialer","year":"2009","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.addr.2011.11.006_bb0080","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.eplepsyres.2010.09.001","article-title":"Progress report on new antiepileptic drugs: a summary of the tenth Eilat Conference (EILAT X)","volume":"92","author":"Bialer","year":"2010","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.addr.2011.11.006_bb0085","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrd2997","article-title":"Key factors in the discovery and development of new antiepileptic drugs (AEDs)","volume":"9","author":"Bialer","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2011.11.006_bb0090","first-page":"1379-1379","article-title":"Uber die Kpstitution der Einwirkugsproduckte von substituierten Harnstoffen uaf Benzyl under uber eingige neue Methoden zurDarstellung der 5,5-Diphenylhydantoine","volume":"41","author":"Blitz","year":"1908","journal-title":"Ber. Dtsch. Chem. Ges."},{"key":"10.1016\/j.addr.2011.11.006_bb0095","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1055\/s-0028-1122960","article-title":"Diebekampfung epileptischer Anfalle und uhrer Forger scheinungen mit Prominal","volume":"58","author":"Blum","year":"1932","journal-title":"Dtsch. Med. Wochenschr."},{"key":"10.1016\/j.addr.2011.11.006_bb0100","first-page":"230","article-title":"The evaluation of mysoline \u2014 a new anticonvulsant drug","volume":"8","author":"Bouge","year":"1953","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.addr.2011.11.006_bb0105","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1212\/WNL.33.3.283","article-title":"Primidone, phenobarbital and PEMA I. Seizure protection, neurotoxicity and therapeutic index of varying combinations in mice","volume":"33","author":"Bourgeois","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.addr.2011.11.006_bb0110","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1212\/WNL.33.3.291","article-title":"Primidone, phenobarbital and PEMA II. Seizure protection, neurotoxicity and therapeutic index of varying combinations in mice","volume":"33","author":"Bourgeois","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.addr.2011.11.006_bb0115","series-title":"Antiepileptic Drugs","first-page":"449","article-title":"Primidone \u2014 chemistry and biotransformation","author":"Bourgeois","year":"1995"},{"key":"10.1016\/j.addr.2011.11.006_bb0120","first-page":"385","article-title":"On the propyl derivatives and decomposition of ethylaceto-acetate","volume":"3","author":"Burton","year":"1882","journal-title":"Am. Chem. J."},{"key":"10.1016\/j.addr.2011.11.006_bb0125","first-page":"468","article-title":"Properties pharamcodynamiques de l'acide n-dipropylacetique et ses derives","volume":"19","author":"Carraz","year":"1964","journal-title":"Therapy"},{"key":"10.1016\/j.addr.2011.11.006_bb0130","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/0024-3205(83)90054-1","article-title":"Acute anticonvulsant activity of structural analogues of valproic acid and changes in brain GABA and aspartate content","volume":"32","author":"Chapman","year":"1983","journal-title":"Life Sci."},{"key":"10.1016\/j.addr.2011.11.006_bb0135","series-title":"Antiepileptic Drugs","article-title":"Other hydantoins: albutoin","author":"Cereghino","year":"1972"},{"key":"10.1016\/j.addr.2011.11.006_bb1010","first-page":"210","article-title":"New anticonvulsant in the treatment of epilepsy (3-methyl-5,5-phenyl-ethyl-hydantoin) (Hydantal)","volume":"44","author":"Clein","year":"1945","journal-title":"Preliminary report. Northwest. Med."},{"key":"10.1016\/j.addr.2011.11.006_bb0140","first-page":"863","article-title":"ONO-2506","volume":"4","author":"de Paulis","year":"2003","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.addr.2011.11.006_bb0145","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrd1756","article-title":"Pregablin","volume":"4","author":"Dworkin","year":"2005","journal-title":"Nat. Rev."},{"key":"10.1016\/j.addr.2011.11.006_bb0150","series-title":"Antiepileptic Drugs","first-page":"421","article-title":"Phenobarbital \u2014 chemistry and other barbiturates","author":"Eadie","year":"1995"},{"key":"10.1016\/j.addr.2011.11.006_bb0155","series-title":"Antiepileptic Drugs","first-page":"541","article-title":"Phenobarbital \u2014 chemistry and other barbiturates","author":"Eadie","year":"2002"},{"key":"10.1016\/j.addr.2011.11.006_bb0160","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1124\/jpet.108.143420","article-title":"Challenges in the search for drugs to treat central nerve systems disorders","volume":"329","author":"Enna","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.addr.2011.11.006_bb0165","first-page":"73","article-title":"Pharmacokinetics and metabolic features of oxcarbazepine and their clinical significance: comparison with carbamazepine","volume":"5","author":"Faigle","year":"1990","journal-title":"Int. J. Clin. Psychopharmacol."},{"key":"10.1016\/j.addr.2011.11.006_bb0170","series-title":"Antiepileptic Drugs: Mechanisms of Action","first-page":"587","article-title":"Succinimides","author":"Ferrendelli","year":"1980"},{"key":"10.1016\/j.addr.2011.11.006_bb0175","article-title":"Pharmacokinetics of two enantiomers of the monohydroxy derivatives of oxcarbazepine in man","volume":"8","author":"Flesch","year":"1999","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2011.11.006_bb0180","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1124\/dmd.109.030593","article-title":"Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its two enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine","volume":"39","author":"Flesch","year":"2011","journal-title":"Drug Metab. Deposit."},{"key":"10.1016\/j.addr.2011.11.006_bb0185","series-title":"New Anticonvulsant Drugs","first-page":"103","article-title":"Eterobarb","author":"Gallagher","year":"1986"},{"key":"10.1016\/j.addr.2011.11.006_bb0190","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0041-008X(61)90014-X","article-title":"Pharmacology of some substituted 2-thiohydanotins with particular reference to anticonvulsant properties","volume":"3","author":"Gesler","year":"1961","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.addr.2011.11.006_bb0195","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1212\/WNL.19.12.1207","article-title":"Clinical evaluation of albutoin","volume":"19","author":"Green","year":"1969","journal-title":"Neurology"},{"key":"10.1016\/j.addr.2011.11.006_bb0200","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1023\/A:1015934321764","article-title":"Structure\u2013pharmacokinetic relationships in a series of valpromide isomers with antiepileptic activity","volume":"6","author":"Haj-Yehia","year":"1989","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2011.11.006_bb0205","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/jps.2600790814","article-title":"Structure\u2013pharmacokinetic relationships in a series of short fatty acid amides that possess anticonvulsant activity","volume":"79","author":"Haj-Yehia","year":"1990","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2011.11.006_bb0210","first-page":"1907","article-title":"Luminal bei epilepsie","volume":"5","author":"Hauptmann","year":"1912","journal-title":"Munch. Med. Wochenschr."},{"key":"10.1016\/j.addr.2011.11.006_bb0215","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/clpt.1990.207","article-title":"The influence of age and gender on the stereoselective metabolism and pharmacokinetics of methylphenobarbitone in humans","volume":"48","author":"Hooper","year":"1990","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2011.11.006_bb0220","first-page":"142","article-title":"Enantioselective pharmacokinetics of ethotoin in humans following single oral doses of the racemate","volume":"4","author":"Hooper","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.addr.2011.11.006_bb0225","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00019052-200304000-00014","article-title":"New CNS-active drugs which are second generation to valproic acid: can they lead to the development of the magic bullet?","volume":"16","author":"Isoherranen","year":"2003","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.addr.2011.11.006_bb0230","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1517\/13543784.9.4.829","article-title":"An assessment of rufinamide as an anti-epileptic in comparison to other drugs in development","volume":"9","author":"Jain","year":"2000","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.addr.2011.11.006_bb0235","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/j.1875-9114.1994.tb02788.x","article-title":"Venous irritation related to intravenous administration of fosphenytoin versus Fosphenytoin","volume":"14","author":"Jamerson","year":"1994","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.addr.2011.11.006_bb0240","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/0028-3908(83)90134-X","article-title":"The effects of analogues of valproic acid on pentylenetetrazol induced seizures and brain GABA content in mice","volume":"22","author":"Keane","year":"1983","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.addr.2011.11.006_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0090-9556(25)00213-2","article-title":"A major pathway of mephenytoin metabolism in man. Aromatic hydroxylation p-hydroxymephenytoin","volume":"8","author":"Kupfer","year":"1980","journal-title":"Drug Metab. Disposit."},{"key":"10.1016\/j.addr.2011.11.006_bb0250","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0022-3565(25)32651-0","article-title":"Stereoselective metabolism of mephenytoin in man","volume":"218","author":"Kupfer","year":"1981","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.addr.2011.11.006_bb0255","series-title":"Antiepileptic Drugs, Mechanism of Action","first-page":"643","article-title":"Sodium valproate","author":"Kupferberg","year":"1980"},{"key":"10.1016\/j.addr.2011.11.006_bb0260","series-title":"Antiepileptic Drugs","first-page":"351","article-title":"Other hydantoins \u2014 mephenytoin and ethotoin","author":"Kupferberg","year":"1995"},{"key":"10.1016\/j.addr.2011.11.006_bb0265","series-title":"Antiepileptic Drugs: Quantitative Analysis and Interpretation","first-page":"297","article-title":"Clinical pharmacology of carbamazepine","author":"Kutt","year":"1978"},{"key":"10.1016\/j.addr.2011.11.006_bb0270","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1212\/WNL.40.3_Part_1.456","article-title":"Pharmacokinetics and safety of phenytoin prodrug given IV in patients","volume":"40","author":"Leppik","year":"1990","journal-title":"Neurology"},{"key":"10.1016\/j.addr.2011.11.006_bb0275","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S0090-9556(25)08746-X","article-title":"Stereoselective metabolism and pharmacokinetics of methylphenobarbitone in humans","volume":"17","author":"Lim","year":"1989","journal-title":"Drug Metab. Disposit."},{"key":"10.1016\/j.addr.2011.11.006_bb0280","series-title":"Valproate","first-page":"1","article-title":"The discovery of valproate","author":"Loscher","year":"1999"},{"key":"10.1016\/j.addr.2011.11.006_bb0285","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrd3076","article-title":"The anticonvulsants market","volume":"9","author":"Mackey","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2011.11.006_bb0290","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1021\/ja01310a040","article-title":"5,5-dipehnylbarbituric acid","volume":"57","author":"McElvian","year":"1935","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2011.11.006_bb0295","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1001\/jama.1938.02790380010004","article-title":"Sodium diphenyl hydantoinate in the treatment of convulsive disorders","volume":"111","author":"Merritt","year":"1938","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2011.11.006_bb0300","first-page":"435","article-title":"Properties pharamcodynamiques de l'acide n-dipropylacetique. Ler memoire Proprietes antiepileptique","volume":"18","author":"Meunier","year":"1963","journal-title":"Therapy"},{"key":"10.1016\/j.addr.2011.11.006_bb0305","doi-asserted-by":"crossref","first-page":"6536","DOI":"10.1021\/ja01120a044","article-title":"Anticonvulsants IV. An investigation of a-\u03b1-(substituted phenyl) succinimides","volume":"75","author":"Miller","year":"1953","journal-title":"J. Am. Chem. Soc."},{"issue":"Suppl. 1","key":"10.1016\/j.addr.2011.11.006_bb0310","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1111\/j.1528-1157.1984.tb05637.x","article-title":"(1984) Valproate: recent findings and perspectives","volume":"25","author":"Morre","year":"1984","journal-title":"Epilepsia"},{"key":"10.1016\/j.addr.2011.11.006_bb0315","first-page":"509","article-title":"Sodium valproate: an old drug with new roles","volume":"30","author":"Nalivaeva","year":"2009","journal-title":"THIPS"},{"key":"10.1016\/j.addr.2011.11.006_bb0320","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S1474-4422(07)70215-6","article-title":"Developing novel antiepileptic drugs (AEDs): challenges, incentives and recent advances","volume":"6","author":"Perucca","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.addr.2011.11.006_bb0325","series-title":"New Anticonvulsant Drugs","first-page":"3","article-title":"Antiepileptic drugs: efficacy and inadequacy","author":"Porter","year":"1986"},{"key":"10.1016\/j.addr.2011.11.006_bb0330","series-title":"Antiepileptic Drugs","first-page":"473","article-title":"Phenobarbital: introduction","author":"Prichard","year":"1980"},{"key":"10.1016\/j.addr.2011.11.006_bb0335","series-title":"Antiepileptic Drugs","first-page":"611","article-title":"Fosphenytoin","author":"Pryor","year":"2002"},{"key":"10.1016\/j.addr.2011.11.006_bb0340","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0022-3565(25)29596-9","article-title":"A comparison of the anticonvulsant, neurotoxic and lethal effects of diphenylbarbituric acid, phenobarbital and diphenylhydantoin in the mouse","volume":"186","author":"Raines","year":"1973","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.addr.2011.11.006_bb0345","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1528-1157.1975.tb04739.x","article-title":"The effects of 5,5-diphenylbarbituric acid on experimental seizures in rats: correlation between plasma and brain concentration s and anticonvulsant activity","volume":"16","author":"Raines","year":"1975","journal-title":"Epilepsia"},{"key":"10.1016\/j.addr.2011.11.006_bb0350","first-page":"531","article-title":"Anticonvulsant therapy, megaloblastic hematophoiesis and folic acid metabolism","volume":"35","author":"Reynolds","year":"1966","journal-title":"Q. J. Med."},{"key":"10.1016\/j.addr.2011.11.006_bb0355","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/0028-3908(62)90073-4","article-title":"Behavioral and central muscle relaxant properties of 2-ethyl-3-methlyvaleramide","volume":"1","author":"Roszkowski","year":"1962","journal-title":"Int. J. Neuropharmacol."},{"key":"10.1016\/j.addr.2011.11.006_bb0360","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3109\/00498258609043567","article-title":"The metabolism of 14C-oxcarbazpien in humans","volume":"8","author":"Shutz","year":"1986","journal-title":"Xenobiotica"},{"key":"10.1016\/j.addr.2011.11.006_bb0365","series-title":"Antiepileptic Drugs: Quantitative Analysis and Interpretation","first-page":"283","article-title":"(1978) Clinical pharmacology of ethosuximide","author":"Sherwin","year":"1978"},{"key":"10.1016\/j.addr.2011.11.006_bb0370","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1177\/0091270007313323","article-title":"Pharmacokinetics of licarbazepine in healthy volunteers: single and multiple oral doses and effect of food","volume":"48","author":"Souppart","year":"2008","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2011.11.006_bb0375","series-title":"Antiepileptic Drugs: Mechanisms of Action","first-page":"563","article-title":"Carbamazepine","author":"Suria","year":"1980"},{"key":"10.1016\/j.addr.2011.11.006_bb0380","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.pain.2008.11.019","article-title":"Mechanisms of analgesia by gabapentin and pregablin \u2014 calcium channel \u03b12-\u03b4 [Cav\u03b12-\u03b4] ligands","volume":"142","author":"Taylor","year":"2009","journal-title":"Pain"},{"key":"10.1016\/j.addr.2011.11.006_bb0385","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1212\/WNL.34.8.1100","article-title":"Disposition of mephenytoin and its metabolite, nirvanol, in epileptic patients","volume":"34","author":"Theodore","year":"1984","journal-title":"Neurology"},{"key":"10.1016\/j.addr.2011.11.006_bb0390","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/ana.410060506","article-title":"Clinical pharmacology of mephenytoin and ethotoin","volume":"6","author":"Troupin","year":"1979","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.addr.2011.11.006_bb0395","first-page":"151","article-title":"Cyclic ureides","volume":"Vol. 15","author":"Vida","year":"1977"},{"key":"10.1016\/j.addr.2011.11.006_bb0400","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1053\/cp.1999.v66.103170001","article-title":"Enantioselective pharmacokinetics of 10-hydroxy carbazepine following oral administration of oxcarbazepine to healthy Chinese subjects","volume":"66","author":"Volosov","year":"1999","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2011.11.006_bb0405","series-title":"New Antiepileptic, Epilepsy Res","first-page":"99","article-title":"Eterobarb","author":"Wolter","year":"1991"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X11002869?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X11002869?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T09:20:58Z","timestamp":1741944058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X11002869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":84,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0169409X11002869"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2011.11.006","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}